Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/330IWUU
via IFTTT